RPS6KB1 and neoplasm: Pre-clinical longitudinal studies that targeted the PI3K and p70S6K pathways with competitive NVP-BEZ235 inhibitor was not as effective at reducing tumor volume and burden as targeting mTOR with AZD8055 or glycolysis with 2-DG mono-therapies.